Synopsis
Drug firm Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV.
Agencies
Drug firm
Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Truvada tablets of Gilead Sciences. Strides Pharma Global, Singapore, has received approval for Emtricitabine and Tenofovir Disoproxil Fumarate tablets in the strengths of 200 mg/300 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.
Drug firm Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Truvada tablets of Gilead Sciences. Strides Pharma Global, Singapore, has received approval for Emtricitabine and Tenofovir Disoproxil Fumarate tablets in the strengths of 200 mg/300 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing. Quoting IQVIA moving annual total (MAT) November 2020 data, Strides Pharma Science said the US market for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is approximately USD 2.4 billion.
Global Ibuprofen Market Expected to Reach USD 1,436 8 Million by 2027 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Ahead of Market: 12 things that will decide stock action on Thursday
SECTIONS
Share
Synopsis
Rohit Singre, Senior Technical Analyst at LKP Securities said, The index has formed a good base near 14,500-14,430 zone and any break below said levels can emerge in more profit booking. Analysts said the index could be in for some consolidation, and believe Nifty testing of the 14,400-14,367 range could put an end to the ongoing strong momentum.
Related
NEW DELHI: Nifty today touched its fresh all time high, but soon saw a bout of profit booking and settled at almost the same level as the previous close. The headline index formed a bearish candle with a long lower shadow similar to a Hanging man pattern for the day.
Search jobs 13-Jan-2021 Clostridium Difficile Infection Drugs Market Size 2021 Share, Trends, Future Demand, Global Research, Top Leading Players by Novartis AG, Baxter, ANI Pharmaceuticals, Mylan N.V, Akorn
The Latest research study released by DBMR “
Global Clostridium Difficile Infection Drugs Market” with 350+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. This report likewise contemplates the worldwide Clostridium Difficile Infection Drugs market status, rivalry scene, market share, development rate, future patterns, market drivers, openings and difficulties, deals channels and wholesalers. Territorially, this report orders the creation, clear